Bragar Eagel & Squire P.C. Educates Investors That Class Action Lawsuits Have Been Filed Against AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), Ocugen Inc (NASDAQ: OCGN), and Tarena International Inc (NASDAQ: TEDU)

July 2, 2021

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), Ocugen Inc (NASDAQ: OCGN), and Tarena International Inc (NASDAQ: TEDU) are headed for not so good days ahead with their investors. Bragar Eagel & Squire, P.C., a shareholder rights law firm known across the nation, informs investors that class actions are initiated on behalf of stockholders of the three companies. Further, the law firm informed that stockholders of the three companies must submit a petition…

Read More >>

Diamedica Therapeutics Inc (NASDAQ: DMAC) Speaks Concerning The Phase 2 REDUX Study In CKD And The Associated Positive Interim Results

July 2, 2021

Diamedica Therapeutics Inc (NASDAQ: DMAC) has updated its Phase 2 REDUX Study In CKD. Over the years, this clinical-stage biopharmaceutical company has worked on finding working solutions for cardio-renal diseases and various neurological disorders. The company is quite impressed with the associated Positive Interim Results.  The study’s activities and achievements Today’s announcement tells a lot about its success in its Phase 2 REDUX trial of DM199, a step it considers crucial…

Read More >>

Umbra Applied Technologies Group Inc. (OTCMKTS: UATG) To Commence Testing of Its Advanced Vertical Helix Wind Turbines

July 1, 2021

Umbra Applied Technologies Group Inc. (OTCMKTS: UATG) has announced that its advanced wind turbine will start field testing in the next 90-120 days.  New Helix Turbines manufactured from 75% recycled material. The Helix Turbine, dubbed V-HET, has been built of carbon fiber, aluminum, steel, and composite materials, making each unit strong to endure the elements. However, it is light to enable it to harness maximum wind power. The tech employs…

Read More >>

American Premium Water Corporation (OTCMKTS: HIPH) To Launch Beta Version of CaliBear JV E-Commerce Platform

July 1, 2021

American Premium Water Corporation (OTCMKTS: HIPH) has announced its new e-commerce platform for the joint venture with CaliBear, will launch its Beta version on July 8, 2021. The company retained Studio 420 to continue the development work and also the implementation of the new website.  American Premium Water to launch the Beta version of the CaliBear website  The company’s CEO, Ryan Fishoff, said, “The Company is excited to announce that…

Read More >>

VoIP-Pal.com Inc. (OTCMKTS: VPLM) Files Petition To Hold Court Of Appeal’s Decision on Case Against Apple and Amazon

July 1, 2021

VoIP-Pal.com Inc. (OTCMKTS: VPLM) has announced that it filed a petition on June 25, 2021, for writ of certiorari with the US Supreme Court. The company owns patents on Voice-over-Internet Protocol tech.  VoIP-Pal wants the Court of Appeals decision deferred until Axle America’s case is determined  The company has requested the Supreme court to review the Court of Appeals for the Federal Circuit’s (CAFC) decision on VOIP-Pal’s proceedings against Amazon.com…

Read More >>

Halberd Corporation (OTCMKTS: HALB) Announces New Disease-Causing Antigen Eradication Technique

July 1, 2021

Halberd Corporation (OTCMKTS: HALB) has announced a potentially game-changing technique for removing disease-causing antigen(s) that does not rely on metallic nanoparticles attached to antibodies.  New disease-causing antigens removal technique uses available equipment in hospitals. This more straightforward technique for removing disease-causing antigen(s) makes use of more standard medical equipment available in clinics and hospitals, as well as our patented extracorporeal therapy technique. The strategy is expected to streamline the commercial…

Read More >>

America Green Inc. (OTCMKTS: ERBB) Starts Implementation of Jumio Facia Recognition Software In Its Vending Machines

July 1, 2021

America Green Inc. (OTCMKTS: ERBB) has announced that it has started implementing facial recognition software from Jumio in the AGM Age Verifying Vending Machine.  Jumio has validated over 300 million IDs. Jumio’s AI-powered authorization and identity software will automatically carry facial recognition for the company’s maiden client onboarding process. So far, Jumio has validated 300 million IDs and will now be incorporated into the AGM’s cannabis and VBD age-verifying vending…

Read More >>

BioNano Genomics Inc (NASDAQ: BNGO) Is Included In Small-Cap Russell 2000® Index, Ashford Hospitality Trust, Inc. (NYSE: AHT) Preparing To Be Included In The Russell 2000®, Russell 3000® And Russell Microcap® Indexes

June 30, 2021

BioNano Genomics Inc (NASDAQ: BNGO) has made it official that it has found a place in the U.S. small-cap Russell 2000® Index. Companies that make it to the list are eligible to be members for one year. BioNano Genomics Inc is a genome analysis company that supports scientists with the tools in clinicians conducting genetic research, patient testing, and diagnostic testing for patients diagnosed with Autism Spectrum Disorder (ASD) and…

Read More >>

While Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) In Russell 3000® and Russell Microcap® Indexes, Inpixon (NASDAQ: INPX) Included In The Russell Microcap® Index

June 30, 2021

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX), a clinical-stage biotechnology company involved in developing allogeneic cell therapies for unmet medical needs, in an official statement, announced that the company had made it to broad-market Russell 3000® Index as well as the Russell Microcap® Index. Inpixon (NASDAQ: INPX) included in Russell Microcap® Index Inpixon (NASDAQ: INPX), the Indoor Intelligence™ company, announced that it had made it to the Russell Microcap® Index. By…

Read More >>

Caladrius Biosciences Inc. (NASDAQ: CLBS) Jumps 4.5% After FDA Approves Its CLBS201 IND in Diabetic Kidney Disease

June 29, 2021

Caladrius Biosciences Inc. (NASDAQ: CLBS) climbed 4.46% after the FDA approved its Investigational New Drug Application for the CLBS201 study. CLBS201 is a CD34+ cell therapy for diabetic kidney disease treatment.  Caladrius evaluating CLBS20’s efficacy and safety  David J. Mazzo, the company’s CEO and President said, “Our latest development program, CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic patients with…

Read More >>